[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100487846":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":24,"responsibleParty":39,"collaborators":10,"id":42,"slug":10,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Florida State University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Adults without obesity",null,"body mass index below 30 kg\u002Fm\\^2",{"label":13,"type":10,"description":14,"interventionNames":10},"Adults with obesity","body mass index above 30 kg\u002Fm\\^2",[16],{"name":17,"affiliation":5,"role":18},"Joseph Watso, PhD","PRINCIPAL_INVESTIGATOR",[20],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","850-644-5260","jwatso@fsu.edu",[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Tallahassee","Florida","32306","United States",{"type":32,"coordinates":33},"Point",[34,35],-84.28073,30.43826,{"lat":35,"lon":34},[38],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},{"type":18,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Joseph Watso","Assistant Professor","100487846",false,"NCT05632406","Breathing & Blood Pressure","Inclusion Criteria:\n\n• Body mass index values of ≤40 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Not weight stable (\\\u003C5% change in body mass over the past six months)\n* Overt cardiovascular, neurological, renal, liver, and\u002For metabolic illness (e.g., diabetes mellitus)\n* Current, or history of uncontrolled, Stage 2 hypertension (blood pressure \\>140 \u002F 90 mmHg; anti-hypertensive medications are permitted)\n* Diagnosed obstructive sleep apnea\n* Previous bariatric surgery\n* Diagnosis or signs (e.g., values below the lower limit of normal) of overt airway disease(s)\n* Current or recent (regular use within the past 6 months) use of tobacco or nicotine products (e.g., cigarettes, vaping)\n* Per the POWERbreathe® company:\n* Patients who have undergone recent abdominal surgery and those with abdominal hernia.\n* Asthma patients who have a very low symptom perception and suffer from frequent, severe exacerbations or with an abnormally low perception of dyspnoea.\n* If a patient is suffering from a ruptured eardrum or any other condition of the ear.\n* Patients with marked elevated left ventricular end-diastolic volume and pressure.\n* Patients with worsening heart failure signs and symptoms after a respiratory\u002Finspiratory muscle training (IMT) session\n* If you are suffering from a cold, sinusitis, or respiratory tract infection, we advise that you do not use your POWERbreathe IMT device.\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant (self-reported and urine pregnancy test conducted), lactating (self-reported), or post-menopausal (self-reported) females\n* Prisoners",true,"ALL","18 Years","45 Years",{"count":52,"type":53},80,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to determine the effect of obesity on cardiovascular responses during various breathing maneuvers.",[57,58],"Healthy","Overweight and Obesity","2026-06-24",{"date":61,"type":62},"2026-06-26","ACTUAL",{"date":64,"type":62},"2023-10-25",{"date":66,"type":53},"2027-06-30",{"name":5,"class":6},1]